Dr Polychronis Pavlidis

Professional statement

Dr Polychronis Pavlidis is a Consultant Gastroenterologist with the clinical experience and expertise to provide a holistic and personalised approach for patients with acute and chronic gastrointestinal symptoms or diseases including irritable bowel syndrome, ulcerative colitis, Crohn’s disease and gastrointestinal complications following cancer treatments and transplantation. 

His private practice is currently based across four clinics in London: The London Bridge Hospital, HCA at The Shard, HCA at Canary Wharf, and King’s College Hospital (Guthrie Wing).

Dr Pavlidis is a JAG accredited endoscopist for upper, lower diagnostic and therapeutic GI procedures (gastroscopy & colonoscopy). He has also been accredited to contribute to the national bowel cancer screening programme (BCS colonoscopy) in England.

Following his medical degree (University of Thessaly, Larissa, Greece, 2006) he undertook post-graduate training in London and the south-east of England, working at international centres of excellence including King’s College Hospital and Guy’s and St Thomas’ NHS Foundation Trust. Dr Pavlidis holds a PhD in Transplantation Immunology and Mucosal Biology from King’s College London (2018) for studying the role of interleukin 22 in inflammatory bowel disease and acute gastrointestinal graft versus host disease. He was the NIHR Academic Clinical Lecturer in Gastroenterology at King’s Health Partners from 2018 to 2021.

As the Upper GI cancer, two-week-wait pathway Lead at King’s he aspires to deliver with his team a high quality, rapid diagnostics service for patients with concerning gastrointestinal symptoms. As the Clinical Governance Lead his priority is to lead the wider luminal gastroenterology team’s efforts in providing safe and evidenced base care with empathy, personalised to the individual’s needs.

Dr Pavlidis holds an adjunct position with King’s College London as a Senior Lecturer at the Department of Inflammation, School of Immunology and Microbial Sciences. He leads an ambitious translational research programme funded by major national funding streams (NIHR, MRC), charities (CCUK, Guts UK) and other stakeholders aiming to deliver stratified medicine approaches in chronic gut inflammation as well as inform evidence-based practice. He has presented his research work at national and international fora receiving multiple awards and published in high impact journals like Nature Communications, Cell Reports and Gut. He has co-authored leading national and international guidlines as well as consensus statements on personalised medicine approaches in IBD and checkpoint inhibitor induced colitis.